Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.41 |
| ▸ | MEN1 | O00255 | 6/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | RECQL | P46063 | 2/20 | 0.37 |
| ▸ | S100A4 | P26447 | 2/20 | 0.37 |
| ▸ | EHMT2 | Q96KQ7 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 2/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28971937 | 0.77 | KMT2A (0.39) | KMT2AMEN1POLBALDH1A1MAPK1 | |
| SCHEMBL1962246 | 0.76 | KMT2A (0.35) | KMT2AMEN1POLBALDH1A1MAPK1 | |
| Water SCHEMBL6608061 | 0.70 | MAOA (0.32) | MAOAMAOB | |
| SCHEMBL2933046 | 0.69 | GABRP (0.37) | KMT2AMEN1POLBALDH1A1MAPK1 | |
| SCHEMBL6314591 | 0.69 | MEN1 (0.40) | KMT2AMEN1POLBALDH1A1L3MBTL1 | |
| SCHEMBL4104071 | 0.67 | MAPT (0.39) | KMT2AMEN1POLBALDH1A1MAPK1 | |
| SCHEMBL94097 | 0.66 | MEN1 (0.41) | KMT2AMEN1POLBALDH1A1MAPK1 | |
| SCHEMBL9080469 | 0.64 | MAPT (0.42) | KMT2AMEN1ALDH1A1MAPK1TSHR | |
| SCHEMBL30983012 | 0.64 | MAPT (0.42) | KMT2AMEN1ALDH1A1MAPK1TSHR | |
| SCHEMBL10344203 | 0.64 | MEN1 (0.55) | KMT2AMEN1POLBALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2112161-B1 | Peptides that lower blood glucose levels | ZEALAND PHARMA AS (DK) | 2014-11-05 | — | — | EP | disclosed |
| EP-2699567-A1 | INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2014-02-26 | — | — | EP | disclosed |
| US-20140045832-A1 | Insulin-Like Growth Factor-1 Receptor Inhibitors | Piramal Enterprises Limited (IN) | 2014-02-13 | — | — | US | disclosed |
| WO-2012145471-A1 | INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-10-26 | — | — | WO | disclosed |
| EP-1904438-B1 | DICYCLOALKYLCARBAMOYL UREAS AS GLUCOKINASE ACTIVATORS | NOVO NORDISK AS (DK) | 2012-02-29 | — | — | EP | disclosed |
| US-8008295-B2 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-08-30 | — | — | US | disclosed |
| EP-1534695-B1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2010-09-29 | — | — | EP | disclosed |
| US-20100041652-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2010-02-18 | — | — | US | disclosed |
| EP-1481077-B1 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2009-11-04 | — | — | EP | disclosed |
| US-20090186871-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2009-07-23 | — | — | US | disclosed |
| WO-1996010035-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1996-04-04 | — | — | WO | disclosed |
| WO-1996009821-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1996-04-04 | — | — | WO | disclosed |
| WO-1996010034-A2 | THIOL-FREE INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1996-04-04 | — | — | WO | disclosed |
| US-5491164-A | DOPEPTIDE ANALOGS | MERCK & CO., INC. (US) | 1996-02-13 | — | — | US | disclosed |
| WO-1995032191-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1995-11-30 | — | — | WO | disclosed |
| WO-1995025092-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1995-09-21 | — | — | WO | disclosed |
| US-5439918-A | Prodrug for cancer therapy | MERCK & CO., INC. (US) | 1995-08-08 | — | — | US | disclosed |
| WO-1995009000-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1995-04-06 | — | — | WO | disclosed |
| WO-1995009001-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1995-04-06 | — | — | WO | disclosed |
| WO-1994010138-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1994-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045832-A1 | Insulin-Like Growth Factor-1 Receptor Inhibitors | IGF1R, IGFBP1, INSR | KMT2A 3601/4885MEN1 519/4885POLB 4721/4885 |
| US-20090186871-A1 | Tyrosine kinase inhibitors | ABL1, JAK2, ERBB2 | KMT2A 1038/4885MEN1 2270/4885POLB 4836/4885 |
| US-20100041652-A1 | TYROSINE KINASE INHIBITORS | ABL1, ERBB2, JAK2 | KMT2A 904/4885MEN1 2761/4885POLB 4790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.